- Conditions
- Sjogren's Syndrome, Dry Eye, Neurotrophic Keratitis
- Interventions
- Eye Exam
- Diagnostic Test
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 27
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neurotrophic Keratitis
- Interventions
- KB801, Placebo
- Biological · Drug
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Irvine, California • Pasadena, California • Carmel, Indiana + 6 more
- Conditions
- Dry Eye, Neurotrophic Keratitis
- Interventions
- Cenegermin Ophthalmic Solution [Oxervate]
- Drug
- Lead sponsor
- Toyos Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Ocular GVHD
- Interventions
- corneal sensation test
- Diagnostic Test
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
- Interventions
- Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
- Drug · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- Cenegermin, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more
- Conditions
- Neurotrophic Keratitis
- Interventions
- rhNGF 20µg/ml, Placebo
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Los Angeles, California • San Diego, California + 8 more
- Conditions
- Corneal Disease, Neuropathy, Dry Eye Disease, Neurotrophic Keratitis
- Interventions
- Quantitative Sensory Test
- Device
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neurotrophic Keratopathy
- Interventions
- RGN-259, Placebo
- Drug
- Lead sponsor
- ReGenTree, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 11
- States / cities
- Lancaster, California • Colorado Springs, Colorado • Fort Collins, Colorado + 7 more
- Conditions
- Dry Eye
- Interventions
- Cyclosporine ophthalmic solution 0.1%
- Other
- Lead sponsor
- Neuro-Ophthalmology of Texas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dry Eye
- Interventions
- Dry Eye Disease
- Diagnostic Test
- Lead sponsor
- Research Insight LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Laguna Beach, California
- Conditions
- Neurotrophic Keratitis
- Interventions
- BRM424 Ophthalmic Solution - Dose1, BRM424 Ophthalmic Solution - Dose2
- Drug
- Lead sponsor
- BRIM Biotechnology Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Leland, North Carolina
- Conditions
- Limbal Stem Cell Deficiency
- Interventions
- Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
- Procedure · Biological
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
- Interventions
- Acthar Gel 80 UNT/ML Injectable Solution
- Drug
- Lead sponsor
- Toyos Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Neurotrophic Keratitis
- Interventions
- Lacripep, Vehicle Ophthalmic Solution
- Drug · Other
- Lead sponsor
- TearSolutions, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Carmel, Indiana • Minneapolis, Minnesota • St Louis, Missouri
- Conditions
- Diabetic Retinopathy, Neurotrophic Keratitis
- Interventions
- Not listed
- Lead sponsor
- Medical Center Ophthalmology Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Neurotrophic Keratopathy
- Interventions
- RGN-259, Placebo
- Drug
- Lead sponsor
- ReGenTree, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 29
- States / cities
- Laguna Hills, California • Loma Linda, California • Colorado Springs, Colorado + 25 more
- Conditions
- Neurotrophic Corneal Ulcer, Neurotrophic Keratitis, Cranial Nerve V Diseases
- Interventions
- Corneal neurotization
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Neurotrophic Keratitis
- Interventions
- cenegermin-bkbj
- Drug
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- San Diego, California • Edgewood, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Ocular Surface Disease, Neurotrophic Keratopathy Stage 1
- Interventions
- Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period., Alternative would be patient exiting the trial and starting on tears or other standard of care.
- Drug · Other
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Neurotrophic Keratitis
- Interventions
- Cenegermin Ophthalmic Solution [Oxervate]
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neurotrophic Keratopathy
- Interventions
- OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 31
- States / cities
- Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
- Conditions
- Neurotrophic Keratitis
- Interventions
- Cenegemin in the DEFENDO Study
- Drug
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- San Diego, California • Edgewood, Kentucky • Boston, Massachusetts + 1 more
- Conditions
- Neurotrophic Ulcer, Neurotrophic Keratitis, Neurotrophic Corneal Ulcer, Neurotrophic Keratoconjunctivitis
- Interventions
- Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]
- Drug
- Lead sponsor
- Sight Medical Doctors PLLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Manhasset, New York